Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer

Figure 1

Cumulative overall survival rates of the 65 enrolled patients with unresectable locally advanced or metastatic gastric cancer undergoing neoadjuvant concurrent chemoradiotherapy or chemotherapy, as assessed using the Kaplan–Meier method. The differences in survival rates were analyzed using the log-rank test.